HSC Exam Practice

Sample response. Immunological memory is the ability of the immune system to respond more rapidly and powerfully to a second exposure to the same antigen than it did to the first. It is stored in long-lived memory B cells (and memory T cells) that persist in lymph nodes and bone marrow after a primary immune response.

Marking notes. 1 mark for defining immunological memory as faster/stronger response on re-exposure to the same antigen. 1 mark for identifying memory B cells (and/or memory T cells) as the cell type responsible.

Sample response. The primary immune response is the body's first encounter with a specific antigen; it has a lag period of 7–14 days to peak antibody production and produces initially IgM antibodies, later class-switched to IgG. The secondary immune response occurs on re-exposure to the same antigen; it has a lag period of only 1–3 days to peak antibody production and produces predominantly high-affinity IgG antibodies. The secondary response also achieves a peak antibody level 10–100× higher than the primary response.

Marking notes. 1 mark for lag period comparison (7–14 days vs 1–3 days). 1 mark for antibody class comparison (IgM then IgG for primary; predominantly IgG for secondary). 1 mark for magnitude comparison (secondary peak is 10–100× higher than primary) or equivalent statement about speed difference.

Sample response. Antibody molecules are proteins with a finite half-life; they are catabolised over weeks to months, so circulating antibody titres decline over time after the initial vaccination response. Memory B cell populations also contract gradually as the antigen stimulus is removed — the surviving memory cells persist but fewer plasma cells are actively secreting antibody. After approximately 10 years, antibody levels against tetanus toxoid fall below the protective threshold. A booster dose acts as a controlled second exposure, triggering a secondary immune response that re-expands memory B cell populations and elevates antibody titres above the protective threshold.

Marking notes. 1 mark for explaining antibody decline (catabolism / finite half-life; titres fall over time). 1 mark for explaining that memory cell populations and/or antibody-secreting plasma cells diminish over years. 1 mark for explaining the booster triggers a secondary immune response that restores antibody levels above the protective threshold.

Sample response. MMR is a live-attenuated vaccine — it contains living but weakened strains of measles, mumps and rubella viruses. Because the attenuated virus can replicate briefly in the host, it presents many viral antigens over a sustained period, closely mimicking natural infection. This triggers a strong primary immune response involving clonal selection, clonal expansion, and formation of large numbers of long-lived memory B and T cells and long-lived plasma cells that may persist for decades, maintaining antibody levels above the protective threshold without boosters. Inactivated (killed) vaccines cannot replicate; they present antigens briefly and generate a weaker primary response with fewer and shorter-lived memory cells, so titres decline faster — requiring booster doses.

Marking notes. 1 mark for correctly identifying MMR as a live-attenuated vaccine. 1 mark for explaining why replication extends antigen exposure and produces a stronger / longer-lasting immune response. 1 mark for explaining why inactivated vaccines need boosters in contrast (no replication → briefer antigen stimulus → shorter-lived memory / declining titres).

Sample response. Cowpox virus (vaccinia) and smallpox virus (variola) share several surface antigenic epitopes. When Phipps was inoculated with cowpox material, his immune system mounted a primary immune response: dendritic cells presented cowpox antigens, matching naive B cells underwent clonal selection and expansion, producing plasma cells (clearing the cowpox infection) and memory B and T cells. These memory cells carried receptors specific to cowpox epitopes that are also present on smallpox virions — cross-reactive immunological memory. When exposed to smallpox six weeks later, these cross-reactive memory cells recognised the shared antigens and mounted a secondary immune response, producing high-affinity IgG within 1–3 days and clearing the smallpox virus before disease could develop.

Marking notes. 1 mark for identifying cross-reactive immunological memory — cowpox and smallpox share antigenic epitopes, so memory cells raised against cowpox also recognise smallpox. 1 mark for describing the primary response to cowpox (clonal selection → memory cell formation). 1 mark for explaining that re-exposure to smallpox triggered a secondary response (rapid IgG production; cleared virus before symptoms — or equivalent).

Sample response. Herd immunity is the indirect protection of unvaccinated or susceptible individuals that occurs when enough members of a population are immune to a pathogen — the pathogen cannot find sufficient susceptible hosts to maintain transmission chains. The threshold proportion of immune individuals required varies because different pathogens have different basic reproduction numbers (R₀ — average number of secondary cases per index case in a fully susceptible population). The herd immunity threshold is approximately 1 − (1/R₀): for measles (R₀ ≈ 12–18) the threshold is ~95%; for polio (R₀ ≈ 5–7) it is ~80–85%. More contagious pathogens require a larger immune fraction because they can spread from one person to more susceptible individuals before the chain breaks.

Marking notes. 1 mark for defining herd immunity (population-level protection when enough people are immune; transmission chains broken). 1 mark for explaining that the threshold varies because different pathogens have different transmissibility / R₀. 1 mark for a correctly directed quantitative example (measles ~95%, polio ~80–85%, or equivalent with correct relative comparison).

Sample response (a). Pre-vaccination titre rises from HI = 12 in 2022 to HI = 22 in 2023 and HI = 30 in 2024 — an increasing trend across seasons. This suggests that each annual vaccination cycle, by triggering a secondary immune response from expanding memory B cell pools, leaves a higher residual antibody level than the previous cycle. Memory B cell populations are reinforced each year, so more antibody-secreting long-lived plasma cells are present at the start of each subsequent season.

Marking notes (a). 1 mark for describing the increasing pre-vaccination titre trend across seasons with at least two data points cited. 1 mark for explaining this as cumulative memory cell reinforcement from repeated vaccination / rising residual antibody from growing memory pool.

Sample response (b). The 4-week post-vaccination peak increased from HI = 95 in 2022 to HI = 140 in 2024 — a 47% increase. In 2022, the cohort's first seasonal vaccination elicited a primary-type response from a largely naive immune pool (participants had relatively few pre-existing influenza memory cells). By 2024, after two prior seasons of matched vaccination, memory B cell populations had expanded substantially through repeated secondary immune responses. When the 2024 vaccine antigen was encountered, the larger memory cell pool could undergo faster and more extensive clonal expansion into plasma cells, producing a higher IgG peak titre within the same 4-week period.

Marking notes (b). 1 mark for comparing the two peak values and stating the direction of difference (HI = 95 vs HI = 140 — higher in 2024). 1 mark for explaining this using memory cell accumulation: larger memory pool → more extensive clonal expansion → higher plasma cell output → higher antibody peak. 1 mark for linking to the secondary immune response concept explicitly (each repeat vaccination triggers a secondary response from growing memory pools).

Sample response (c). Even though residual titres at end of season are improving (38 → 45 → 55), annual revaccination remains necessary for influenza because the influenza virus undergoes rapid antigenic variation — primarily antigenic drift, in which point mutations accumulate in the surface proteins haemagglutinin (HA) and neuraminidase (NA). Each year's circulating influenza strains carry slightly different surface epitopes from those used in prior vaccines. Memory B and T cells specific to last year's vaccine strain may not recognise the new season's variant antigen with sufficient affinity, meaning the secondary immune response is weaker or fails entirely against a drifted strain. Without an updated vaccine matched to current circulating strains, the memory cells generated in prior seasons provide inadequate protection. By contrast, smallpox (a non-mutating poxvirus) could be eradicated because memory cells remained cross-protective across all strains.

Marking notes (c). 1 mark for identifying influenza's rapid antigenic variation (antigenic drift in HA/NA) as the key reason. 1 mark for explaining that drifted strains carry different surface epitopes, reducing the effectiveness of prior-season memory cells. 1 mark for connecting to the data — even though titres above threshold persist end-of-season, these antibodies target last year's strain, not this year's drifted variant.

Sample response. Vaccination-driven disease eradication exploits the cellular mechanisms of the primary and secondary immune responses at both individual and population levels. When a vaccine antigen enters the body, dendritic cells present it in lymph nodes; clonal selection identifies the specific naive B cell whose receptor matches the antigen; clonal expansion produces a large clone of plasma cells (secreting antibodies that may clear any mild vaccine-associated symptoms) and long-lived memory B and T cells. This primary response produces immunological memory without the risks of the full disease. On re-exposure to the real pathogen, memory B cells are rapidly activated — clonal expansion into plasma cells generates high-affinity IgG within 1–3 days (secondary response), clearing the pathogen before disease manifests. At the population level, when a sufficient proportion of individuals hold this memory-based secondary immune readiness, the pathogen cannot sustain transmission: each infected individual infects too few new susceptible people (effective R drops below 1), and transmission chains collapse. For smallpox, the vaccinia-based vaccine produced durable cross-reactive memory cells that persisted for many years without requiring boosters; the eradication campaign progressively immunised the global population above the herd immunity threshold (~95%), breaking transmission in every reservoir until the last natural case occurred in 1977 and eradication was declared in 1980. The virus was antigenically stable — it did not undergo significant mutation to escape vaccine-induced memory — so the same cellular mechanism could be applied uniformly across decades and geographies. Influenza presents a fundamentally different challenge. The virus undergoes rapid antigenic drift (accumulation of point mutations in surface proteins HA and NA) and periodic antigenic shift (reassortment producing novel subtypes). Each year's circulating strains express slightly different antigenic epitopes from those targeted by memory cells generated in prior seasons. A secondary immune response requires a close antigen match between the memory B cell receptor and the re-encountered antigen; if the virus has drifted sufficiently, the memory cell's receptor has reduced affinity for the new epitopes and may not trigger an adequate secondary response. This means that while the secondary immune response mechanism is intact in vaccinated individuals, the practical efficacy of that response is degraded by antigenic variability — hence annual revaccination is required to keep memory cell populations matched to circulating strains. Achieving herd immunity against influenza is further complicated because the threshold itself shifts as new variants (with different R₀ values) emerge, requiring continuous surveillance and rapid vaccine reformulation. An mRNA platform can theoretically accelerate the production of variant-matched vaccines, but the biological limitation remains: even perfect vaccination coverage would not produce eradication if the virus can re-escape immune memory through antigenic evolution. The lesson's lesson from smallpox eradication is therefore applicable to influenza only in principle (cellular mechanism is the same) but not in practice: eradication requires a stable antigen target, not just a sufficient vaccination coverage percentage.

Marking criteria (8 marks).

1 mark — Correctly describes the cellular mechanism of the primary immune response: clonal selection of specific naive B cells → clonal expansion → plasma cells (antibody secretion) + memory B/T cells.

1 mark — Correctly describes the secondary immune response mechanism: re-activation of memory B cells → rapid clonal expansion → high-affinity IgG within 1–3 days, clearing pathogen before disease.

1 mark — Explains how these cellular mechanisms translate to population-level protection (herd immunity): enough individuals with secondary-response readiness reduces effective R below 1, breaking transmission chains.

1 mark — Uses smallpox eradication specifically: vaccinia vaccine produced cross-reactive, durable memory; global vaccination above the herd immunity threshold (noting vaccinia's antigenic stability) enabled eradication by 1980.

1 mark — Introduces antigenic drift/shift in influenza as the biological barrier that degrades the secondary immune response: drifted strains have different epitopes, reducing affinity of prior-season memory B cell receptors for current antigens.

1 mark — Explains the practical consequence: memory cells from prior vaccination may not trigger a fully effective secondary response against a drifted strain → annual revaccination required → eradication not achievable by current vaccination strategy.

1 mark — Makes an explicit evaluative comparison: the cellular mechanism of secondary response is the same in both cases, but smallpox had a stable antigen target while influenza does not — hence the mechanism that enabled smallpox eradication cannot, in practice, achieve influenza eradication.

1 mark — Demonstrates coherent, extended scientific reasoning throughout the response using precise terminology (clonal selection, clonal expansion, memory B cell, IgG, herd immunity, antigenic drift, effective R) and links cellular biology to population-level outcomes in a logically structured argument.